Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04747236
Recruitment Status : Recruiting
First Posted : February 10, 2021
Last Update Posted : March 19, 2021
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
Enrica Marchi, MD, University of Virginia

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022